173 related articles for article (PubMed ID: 35031634)
1. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
3. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
5. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
Kimura T; Takami T; Piao Y; Ntalla I; Saji S
Breast Cancer Res Treat; 2024 Jul; 206(1):91-103. PubMed ID: 38704772
[TBL] [Abstract][Full Text] [Related]
7. A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast Cancer.
Pan WK; Ren SY; Zhu LX; Lin BC
Am J Clin Oncol; 2024 Feb; 47(2):71-80. PubMed ID: 37871164
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
9. Platinum-containing regimens for triple-negative metastatic breast cancer.
Egger SJ; Chan MMK; Luo Q; Wilcken N
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
[TBL] [Abstract][Full Text] [Related]
10. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
Aly A; Shah R; Hill K; Botteman MF
Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
[TBL] [Abstract][Full Text] [Related]
11. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
[TBL] [Abstract][Full Text] [Related]
13. Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier.
Chung WP; Yang CT; Chen HY; Su CY; Su HW; Ou HT
J Formos Med Assoc; 2022 Jan; 121(1 Pt 2):319-328. PubMed ID: 34006465
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment
Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
[TBL] [Abstract][Full Text] [Related]
15. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years.
Sieluk J; Yang L; Haiderali A; Huang M; Hirshfield KM
Future Oncol; 2021 Jul; 17(20):2581-2592. PubMed ID: 33764155
[No Abstract] [Full Text] [Related]
17. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.
Celik A; Berg T; Jensen MB; Jakobsen E; Nielsen HM; Kümler I; Glavicic V; Jensen JD; Knoop A
Breast Cancer (Auckl); 2023; 17():11782234231203292. PubMed ID: 37810797
[TBL] [Abstract][Full Text] [Related]
18. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
[TBL] [Abstract][Full Text] [Related]
19. Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
Singh J; Asad S; Zhang Y; Nock W; Adams E; Damicis A; Ramaswamy B; Williams N; Parsons HA; Adalsteinsson VA; Winer EP; Lin NU; Partridge AH; Overmoyer B; Stover DG
Clin Breast Cancer; 2020 Feb; 20(1):e20-e26. PubMed ID: 31631016
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Zhang J; Wang Z; Hu X; Wang B; Wang L; Yang W; Liu Y; Liu G; Di G; Hu Z; Wu J; Shao Z
Int J Cancer; 2015 Jan; 136(1):204-11. PubMed ID: 24824628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
